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Abstract
Growth factors promote plasticity in injured brain and improve impaired functions. For clinical
application, efficient approaches for growth factor delivery into the brain are necessary. Poly(ester
amide) (PEA)-derived microspheres (MS) could serve as vehicles due to their thermal and
mechanical properties, biocompatibility and biodegradability. Vascular endothelial growth factor
(VEGF) exerts both vascular and neuronal actions, making it suitable to stimulate post-stroke
recovery. Here, PEA (composed of adipic acid, L-phenyl-alanine and 1,4-butanediol) MS were
loaded with VEGF and injected intracerebrally in mice subjected to cortical stroke. Loaded MS
provided sustained release of VEGF in vitro and, after injection, biologically active VEGF was
released long-term, as evidenced by high VEGF immunoreactivity, increased VEGF tissue levels,
and higher vessel density and more NG2+ cells in injured hemisphere of animals with
VEGF-loaded as compared to non-loaded MS. Loaded MS gave rise to more rapid recovery of
neurological score. Both loaded and non-loaded MS induced improvement in neurological score
and adhesive removal test, probably due to anti-inflammatory action. In summary, grafted PEA
MS can act as efficient vehicles, with anti-inflammatory action, for long-term delivery of growth
factors into injured brain. Our data suggest PEA MS as a new tool for neurorestorative approaches
with therapeutic potential.
1. Introduction
Ischemic stroke causes brain damage with loss of
neurons, glial cells, and vasculature, leading to long-
term disability and death. Thrombolysis and throm-
bectomy reduce injury and functional impairments
if administered during the first hours after the insult
(Hacke et al 2008), but effective treatments to pro-
mote recovery in the chronic phase are lacking (Di
Carlo 2009, Feigin et al 2014). Growth factors can
promote neurogenesis and angiogenesis (Lee and Son
2009), two processes that play important roles for
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functional restoration after stroke. Among growth
factors, vascular endothelial growth factor (VEGF)
has been shown to regulate formation of new blood
vessels and proliferation and differentiation of neur-
onal precursors (Rosenstein et al 1998, Palmer et al
2000, Krum et al 2002, Sun et al 2003), to promote
post-stroke recovery (Hayashi et al 1998, Zhang et al
2000b,Wittko et al 2009) and also to be neuroprotect-
ive (Sun et al 2003).
These findings have raised the possibility that
administration of growth factors to the injured brain
might be developed into a new therapeutic strategy
in stroke patients. However, growth factors are large
molecules with limited ability to penetrate the blood-
brain barrier (BBB) (Lo et al 2001, Pardridge 2005).
Sustainable delivery of VEGF is also difficult due to
high degradation rate and short half-life following
© 2020 The Author(s). Published by IOP Publishing Ltd
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systemic administration (Storkebaum et al 2004,
Orive et al 2009).
One strategy to overcome the problems with
growth factor delivery is to use biomaterials as car-
riers. Implantation of such materials promotes con-
trolled and sustainable release in the microenvir-
onment (Orive et al 2009, Elliott Donaghue et al
2014), and allows for efficient long-term delivery of
growth factors into the brain parenchyma (Ferreira
et al 2007, Emerich et al 2010). Polymeric micro-
particles appear particularly promising for this pur-
pose (Zhuang et al 2017), and can be delivered dir-
ectly into the target loaded with different drugs or
molecules. For example, poly(lactic-co-glycolic-acid)
(PLGA) microspheres (MS) implanted into striatum
of dopamine-denervated rats provided continuous
release of VEGF and glial cell line-derived neuro-
trophic factor (GDNF), promoting functional recov-
ery in this model of Parkinson’s disease (Herran et al
2013b). Similarly, VEGF-loaded PLGA nanospheres
placed directly into the cerebral cortex improved
behavioral deficits and stimulated angiogenesis in a
mouse model of Alzheimer’s disease (Herran et al
2013a). Supporting the usefulness of this strategy for
VEGF delivery also in stroke, prolonged release of
VEGF from PLGA microcarriers increased angiogen-
esis around the striatal implantation site and facil-
itated migration of immature neurons towards the
ischemic tissue (Quittet et al 2015).Moreover, VEGF-
loaded PLGA MS with attached human neural stem
cells promoted neovascularization in the stroke cav-
ity (Bible et al 2012).
Although PLGA is the most common biodegrad-
able polymer used for tissue engineering (Makadia
and Siegel 2011), some limitations have been repor-
ted, including moderate toxic effects (Sundback et al
2005, Dailey et al 2006). Additionally, PLGA is a poly-
ester that degrades by bulk erosion through hydro-
lysis of ester bonds, leading to rapid mass loss. Acidic
degradation byproducts lower local pH, which may
cause cell and tissue damage (Hemmrich et al 2008,
London et al 2011, Makadia and Siegel 2011, Liu et al
2012). Unlike polyesters including PLGA, after biode-
gradation, poly(ester amide)s (PEAs) release weaker
acidic products in lower quantities, such as neutral
(zwitterionic) α-amino acids and diols, with relat-
ively weak fatty diacids, making them less harmful
for cells (Fonseca et al 2014). The PEAs belong to a
less explored family of biodegradable polymers com-
posed of naturally occurring α-amino acids, which
are released upon biodegradation promoting regener-
ative processes in tissues (Chu 2012, Andres-Guerrero
et al 2015, Katsarava et al 2016). The PEAs have been
shown to be useful for different biomedical applic-
ations (Lee et al 2002, Markoishvili et al 2002, Jikia
et al 2005, Huang et al 2006, 2009, Knight et al 2014,
DeFife et al Andres-Guerrero et al 2015). We were
the first to demonstrate that PEA MS can provide
sustained release of Wnt3A, BMP4 and cyclopamine,
promoting in vitro differentiation of human induced
pluripotent stem cells to cortical neurons (Meman-
ishvili et al 2016).
Here we show that MS made of biocompatible
and biodegradable PEA (composed of adipic acid, L-
phenyl-alanine and 1,4-butanediol (PEA 4F4)) give
rise to sustained release of loaded VEGF in vitro
and, when injected into stroke-injured cerebral cor-
tex, that both non-loaded and VEGF-loadedMS pro-
mote post-stroke recovery, the loaded ones inducing
more rapid improvement. Our findings strongly sup-
port the usefulness of PEA MS for local, long-term
intracerebral delivery of compounds which do not
penetrate BBB. In addition, the data indicate that not
only the released VEGF but also the injected PEAMS
themselves promote behavioral recovery after stroke.
2. Materials andmethods
2.1. Generation of MS
Poly(ester amide) 4F4, composed of adipic acid, L-
phenyl-alanine and 1,4-butanediol (4F4; referring
to number of methylene groups in adipic acid,
phenylalanine and number of methylene groups in
butanediol, respectively) was synthesized by solution
polycondensation of di-p-toluenesulfonic acid salt of
bis(α-amino acid) α,ω-alkylene diesters with active
diesters of dicarboxylic acid as previously described
(Tsitlanadze et al 2004). Polymer structure is as fol-
lows:
We explored the possibility to load PEA 4F4
MS with VEGF for sustainable release. We used
VEGF 121, which lacks heparin-binding domains
and, therefore, is more diffusible than other iso-
forms (Kaplan et al 2016). Also, VEGF 121 is
more angiogenic (Zhang et al 2000a). The growth
factor was loaded in MS using water-in-oil-in-water
(W1/O/W2) double emulsion solvent evaporation
technique, which we have previously used for suc-
cessfully loading PEA 4F4 MS with Wnt3A, BMP4
and cyclopamine (Memanishvili et al 2016). Briefly,
250mg of PEA 4F4 were dissolved in 5ml chloroform
(⩾99.5%, 100–200 ppm amylenes, Sigma-Aldrich) at
room temperature and 2.5 µg of lipase (from por-
cine pancreas Type II, 100–500 units mg−1, Sigma-
Aldrich) were added. Lyophilized VEGF 121 (Pepro
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Tech) was resuspended according to the manufac-
turer’s instructions to obtain a stock solution of pro-
tein. To prepare the primary emulsion, 300 µl of pro-
tein solution containing 30 µg recombinant human
VEGF 121 in 0.1% bovine serum albumin (BSA) in
milli-Q water (Merck) were emulsified with poly-
mer solution using sonicator (Branson Sonifier SLPe-
150D) with a microtip on ice for 2 min. This primary
emulsion was then emulsified with 10 ml pre-filtered
2.5% (w/v) polyvinyl alcohol (PVA, 13–23 000 Mw
87%–89% hydrolyzed, Sigma-Aldrich) solution. The
resulting double emulsion was immediately trans-
ferred into a beaker containing 800 ml of the pre-
filtered 0.5% (w/v) PVA solution and stirred continu-
ously (IKA magnetic stirrer, medium speed) for 24 h
at room temperature to allow the organic solvent to
evaporate.
Following complete evaporation, solidified PEA
4F4 MS were washed three times with milli-Q water
and harvested via vacuum filtration. The particle sus-
pension was passed through a 40 µm pore sterile
filter (BD Biosciences) and freeze-dried (FreeZone
Plus 6, Labconco freeze dry system) for 48 h. Dried
PEA 4F4 MS were stored at −20 ◦C to prevent
inactivation of VEGF. As control, non-loaded PEA
4F4 MS were prepared using the same method as
described above but without protein. For steriliza-
tion, PEA 4F4MS were placed on a bench-top/orbital
3D shaker (VWR) with speed at 20 rpm and exposed
to ultraviolet-light overnight in a laminar flow
hood. Previous studies have shown that after this
method of sterilization, MS and loaded bio-factors
remained stable and bio-active (Chen et al 1986, Li
et al 2000, Schaar et al 2010, Memanishvili et al
2016).
2.2. Electronmicroscopy and size distribution
Freeze-dried PEA 4F4 MS were mounted on a spe-
cimen stub covered with adhesive carbon. Car-
bon tabs were sputter-coated with chromium and
analyzed in a JEOL JSM-7800-F scanning elec-
tron microscope (JEOL ltd, Tokyo, Japan). Sec-
ondary electrons for surface study were detected
at 1.5 kV.
For transmission electron microscope analyses,
4F4 MS were mixed with PolyBed® 812 (Poly-
sciences Inc) polymerized for 48 h in an oven
at +60 ◦C. Specimens were sectioned using a
Leica EM UC7 ultramicrotome (Leica Biosystems).
The 60 nm thick sections were carefully moun-
ted on Pioloform-coated copper grid 75 mesh and
examined in a FEI Tecnai Biotwin 120 kV electron
microscope.
The average diameter of PEA 4F4 MS was estim-
ated based on measurements on about 100 MS from
three different batches, using the scanning electron
microscope software Smile View (version 2.0, JEOL).
Average values were reported.
2.3. Analysis of encapsulation efficiency and
protein release
Amount of encapsulated protein per unit weight of
MS was determined by an extraction method. Five
mg of VEGF-loaded PEA 4F4 MS were dissolved in
1 ml chloroform by agitating using a shaker for 1.5 h.
One ml phosphate-buffered saline (PBS) (pH = 7.4)
solution containing 0.05%Tween 20 and 1%BSAwas
then added, and the mixture was vigorously shaken
and kept rotating overnight (VWR Tube Rotator,
speed 20 rpm) in order to extract total protein from
the organic solution into the aqueous phase. After
centrifugation at 10 000× g for 10 min at+4 ◦C, the
aqueous phase was analyzed. Concentration of VEGF
was determined by ELISA development kit (R&DSys-
tems) in quadruplicate for three independent experi-
ments.
Encapsulation efficiency was expressed as per-
centage of measured loaded protein over the initial
concentration used for production and represents the
average of three different measurements. The total
volumetric loading was expressed as the volume of
VEGF loaded into theMS divided by the total volume
of the MS.
Release profile of encapsulated protein from PEA
4F4MSwas determined by incubating 5mg of VEGF-
loaded MS in a test tube with 1 ml of PBS (pH= 7.4)
solution containing 0.05% Tween 20 and 1% BSA at
+37 ◦C. At defined time intervals (t = 1, 2, 3, …
90 d), samples were centrifuged at 9000× g for 5min,
and medium was removed and replaced with 1 ml
fresh buffer. Concentration of VEGF was determined
by ELISA development kit (R&D Systems) in quad-
ruplicate. Release profiles were expressed in terms of
daily release (ng ml−1), and cumulative release (% of
total encapsulated protein obtained in encapsulation
efficiency determination) and were plotted versus
time.
After 90 d of incubation in buffer, VEGF-loaded
MS were analyzed using a scanning electron micro-
scope for surface monitoring.
2.4. Animals and experimental design
Thirty-one male, 8 weeks old, C57BL/6 mice (body
weight 25–27 g, Charles River, Germany) were used.
Mice were subjected to distal middle cerebral artery
occlusion (dMCAO) (n = 25), or sham proced-
ure (n = 6). Seven days after surgery, all sham-
treated animals received PBS injection and dMCAO-
subjected mice were injected with either PBS (n= 7),
non-loaded MS (n= 9) or VEGF-loaded MS (n= 9)
into cerebral cortex ipsilateral to dMCAO or sham
procedure. Animals were kept in 12 h light/12 h
dark cycles with ad libitum access to food and water.
All procedures were conducted in accordance with
guidelines set by the Malmö-Lund Ethical Commit-
tee for the use of laboratory animals and the European
Union directive on the subject of animal rights.
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2.5. Distal middle cerebral artery occlusion
Animals were anesthetized with isoflurane (3.0%
induction, 1.5% maintenance) mixed with air, and
were injected locally with marcaine for pain relief
(20 µl of 2.5 mg ml−1 stock solution, Astra Zeneca).
During anesthesia and in the early recovery period
(1 h), animals were placed on a heating pad to main-
tain+37 ◦C body temperature. Permanent occlusion
of the distal branch of the right middle cerebral artery
was performed as described previously (Chen et al
1986). Briefly, after shaving the skin, an incision was
made between the right eye and ear. Muscles cover-
ing the cranium were cut and opened, and a small
hole was then drilled in the cranium at the level of
the distal portion of the right middle cerebral artery.
Dura mater was removed, and the artery was visu-
alized and occluded by cauterization. The artery was
then cut off to make sure that there was no remaining
blood flow to the corresponding cortical region. After
skin had been sutured, mice were injected with 1.5 ml
Ringer’s solution intraperitoneally, returned to their
cages, and put on a heating pad. In sham-operated
mice, the distal portion of the middle cerebral artery
was exposed but not occluded. Animals were alloc-
ated randomly to stroke or sham surgery and to the
different experimental groups.
2.6. MS injection
Seven days after dMCAO, sterilized PEA 4F4 MS
were resuspended in PBS to a final concentration of
10 µg µl−1. One µl of PBS with or without non-
loaded or VEGF-loaded MS was then injected ste-
reotaxically at a speed of 0.5 µl min−1 into the
cerebral cortex at the following coordinates: 1.1 mm
anterior from bregma, 1.4 mm lateral from midline
and 1.5 mm ventral from brain surface. Tooth bar
was set at −3.3 mm. The needle was left in place for
5 min after all solution had been injected, and was
then slowly removed during 1min. Finally, thewound
was cleaned and sutured, and mice were returned to
cages with heating pad.
2.7. Behavioral tests
During testing, evaluators were blinded for the four
experimental groups: (1) sham-treated and PBS-
injected (‘Sham + PBS’); (2) stroke-subjected and
PBS-injected (‘dMCAO+ PBS’); (3) stroke-subjected
and non-loaded MS-injected (‘dMCAO + non-
loaded MS’); and (4) stroke-subjected and VEGF-
loadedMS-injected (‘dMCAO+ VEGF-loadedMS’).
Modified neurological severity score (mNSS). The
mNSS represents a composite of motor (muscle
status, abnormal movement), sensory (visual, tactile
and proprioceptive), reflex and balance tests (Schaar
et al 2010). In the version of mNSS modified for mice
(Li et al 2000), the severity of impairment is defined
by the score on a scale from 0 to 14 (normal score= 0,
maximumdeficit score= 14). A composite score of 10
to 14 corresponds to severe, 5 to 9 to moderate, and 1
to 4 to mild impairment.
Adhesive removal test. To assess sensorimotor
impairment, we also performed the adhesive removal
test (Bouet et al 2007) as follows: Before each test-
ing sequence, mice were placed in a transparent Per-
spex box (15 × 25 cm) for a 1 min habituation
period. Thereafter, two adhesive tapes of equal size
(0.3× 0.4 cm) were applied with an equal pressure on
each forepaw so that they covered the hairless part.
The order of placing the adhesive tape (right or
left) was alternated between each animal and each
session. Mice were then replaced in the Perspex box
and the times to contact and to remove each adhesive
tape were measured with a maximum of 2 min. Mice
were trained once daily for 14 d before dMCAO sur-
gery in order to obtain optimal level of performance
and limit inter-individual variation. This test was per-
formed during 5 d at 1, 3, and 7 weeks after injection,
and the average of the last 3 d of each test week was
calculated.
2.8. Immunohistochemistry
At 8 weeks after dMCAO, animals were deeply anaes-
thetized with an overdose of pentobarbital and per-
fused transcardially with ice-cold saline followed
by 4% paraformaldehyde (PFA) (Sigma-Aldrich).
After post-fixation overnight (4% PFA), brains were
placed in 20% sucrose (Sigma-Aldrich) for 24 h.
Coronal sections with 40 µm thickness were cut on
a freezing microtome (Leica, Germany) and kept at
−20 ◦C in cryoprotective solution. Sections were pre-
incubated in blocking solution (5% normal donkey
serum and 0.25% Triton X-100 in 0.1 M potassium-
phosphate buffer) for 1 h at room temperature,
followed by incubation with primary antibodies
overnight at +4 ◦C (supplemental table S1 (available
online at stacks.iop.org/BMM/15/065020/mmedia)).
Fluorophore-conjugated secondary antibodies (Jack-
son ImmunoResearch Laboratories, Inc.) were
diluted in blocking solution (1:200) and applied for
2 h. Nuclei were stained with Hoechst (Molecular
Probes, ThermoFisher Scientific) for 10 min and
sections were mounted with a medium contain-
ing DABCO as antifading reagent (Sigma Aldrich).
Images were obtained using epifluorescence (BX61,
Olympus) and laser scanning confocal (LSM 780,
Zeiss) microscopes and a Virtual Slide Scanner (VS-
120-S6-W, Olympus).
2.9. Quantifications
All quantifications and statistical analyses were
performed by researchers blinded to the experi-
mental groups. Lesion volume was assessed in NeuN-
diaminobenzidine (DAB)-stained sections (n = 4).
Single labeling for NeuN was performed with biot-
inylated horse anti-mouse antibody and visualized
with avidin-biotin-peroxidase complex (Elite ABC
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kit; Vector Laboratories), followed by peroxidase-
catalyzed DAB reaction. Intact areas, identified by
NeuN+ cells in the ipsilateral and contralateral hemi-
spheres, were delineated and then measured using
newCAST software (Visiopharm). Lesion area was
calculated by subtracting the non-lesioned (stained)
area in the injured hemisphere from the corres-
ponding area in the contralateral hemisphere. Lesion
volume was then obtained by multiplying the lesion
area by the distance between the sections.
At 8 weeks after stroke, numbers of ED1+ and
Iba1+ cells were counted and their morphological
characterization was performed in the whole ipsilat-
eral hemisphere in three coronal sections at 0.62, 0.86,
and 1.1 mm anterior from bregma (selected to be the
location of stroke damage and MS injection) using
an epifluorescencemicroscope under a 40× objective.
Total number of immunopositive cells was estimated
stereologically using newCAST software. At least 250
cells per animal were counted in a predefined fraction
of the area of interest.
Area of VEGF-immunoreactivity was determined
in three images of three coronal sections at 0.62, 0.86,
and 1.1 mm anterior from bregma by image ana-
lysis using CellSens Dimension 2010 software (Olym-
pus). The images were selected based on the location
of the stroke-induced damage and the MS injection
site. Quantification was carried out in the dorsal half
of the ipsilateral hemisphere. In each section, areas
of immunoreactivity were identified using defined
threshold for specific signal.
Using these defined parameters, the images of
each region were analyzed by the software, which
calculated the total area covered by pixels/specific
immunopositive signal. The values corresponding to
total VEGF-immunopositive areas were averaged and
expressed as the percentage of area covered by VEGF
per animal. The same stereological estimation was
used to analyze angiogenesis expressed as vessel dens-
ity by area of CD31 immunoreactivity in the injured
hemisphere.
Numbers of ED1+ and Iba1+ cells, as well as
their morphological characterization, were quanti-
fied in the ipsilateral hemisphere in three coronal
sections at 0.62, 0.86, and 1.1 mm anterior from
bregma using an epifluorescence microscope under
a 40× objective (BX61, Olympus). We also used
a previously established protocol for analysis of
the degree of activation of Iba1+ microglia based
on their morphological appearance (Thored et al
2009). Microglia with long and elaborated processes
were classified as ramified, and considered as rest-
ing, non-activated microglia, and those with short
and non-complex processes were classified as inter-
mediate microglia. Finally, Iba1+ microglia cells
without processes and somewhat rounded cell body
were classified as amoeboid or rounded. They were
regarded as activatedmicroglia, expressing high levels
of ED1.
Total number of immunopositive cells was estim-
ated stereologically using newCAST software. Around
300 cells per animal were counted in a predefined
fraction of the area of interest. Similarly, the total
numbers of NG2+ and VEGF+/NG2+ cells were
quantified stereologically in the ipsilateral and con-
tralateral hemisphere. Colocalization of different
markers was in all cases validated using a confocal
microscope (LSM 780, Zeiss). For ED1 quantifica-
tion, a microglia cell, stained with Iba1, was con-
sidered as positive when at least 25% of the cell body
was covered by ED1 staining.
2.10. Statistical analysis
Statistical analysis was performed with Prism 6 Soft-
ware (GraphPad), using one-way analysis of variance
(ANOVA), two-way ANOVA, χ2 test or two-tailed
unpaired t-test, with significance level at P < 0.05.
Results are expressed as mean ± standard deviation
(SD).
3. Results
3.1. PEA 4F4MS can be efficiently loaded with
VEGF
Scanning electron microscopy revealed clear surface
differences between VEGF-loaded and non-loaded
MS. While the non-loaded spheres appeared rather
smooth (figure 1(A)) with small pores on their sur-
face (figure 1(B)), the VEGF-loaded spheres had a
rougher surface (figures 1(C) and (D)). As shown
with transmission electron microscopy, the inner
ultrastructure of the VEGF-loaded spheres exhib-
ited rounded holes (figure 1(E)) in contrast to the
non-loaded spheres, which were homogenous (fig-
ure 1(F)). These differences in morphology provide
evidence for the presence of VEGF in the loaded MS.
Accumulation of VEGF into PEA 4F4 MS was also
supported by a difference in the size distribution of
the particles (P value = 0.0003, χ2 test), showing
higher proportion of MS with a diameter between
21 and 30 µm and, conversely, lower proportion of
MS with a diameter from 1 to 10 µm and from 11 to
20 µm among loaded as compared to non-loadedMS
(figure 1(G)).
The encapsulation efficiency of VEGF in MS,
which is an important parameter to assess the use-
fulness of VEGF-loaded MS, was 62.7 ± 2.5% of the
initial amount of VEGF. Total volumetric loading was
0.12.
Next, we analyzed the release profile of VEGF
from loaded PEA 4F4 MS in vitro during 90 d by
ELISA. The broad size distribution of the spheres (fig-
ure 1(G)) seemed to have an impact on the release
profile. The profile was characterized by a rapid ini-
tial release of 5.0 ± 0.34 ng d−1 of VEGF per mg
MS during the first 24 h, most likely due to acceler-
ated protein diffusion from the surface of the larger
spheres. This was followed by a sustained release of
5
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Figure 1.Morphology and VEGF release profile of PEA 4F4 MS. (A)–(D) Scanning electron micrographs at different
magnifications of non-loaded (A)–(B) and VEGF-loaded (C)–(D) PEA 4F4 MS. Arrows depict small pores on the surface of
non-loaded spheres. (E)–(F) Transmission electron micrographs of non-loaded (E) and VEGF-loaded (F) PEA 4F4 MS. Arrows
(F) depict rounded holes in the VEGF-loaded spheres, not present in non-loaded ones (E). (G) Size distribution of non-loaded
and VEGF-loaded PEA 4F4 MS (average of 100 MS from three batches for respective group). ∗P < 0.05, Student’s unpaired t-test.
(H), ELISA quantification of VEGF concentration released into the buffer from VEGF-loaded PEA 4F4 MS at different
time-points, presented as daily (left axis) or cumulative release (right axis) (n= 12). (I)–(K) Scanning electron micrographs at
different magnifications of VEGF-loaded PEA 4F4 MS after incubation in PBS containing tween and BSA for 90 d. Scale
bars= 2 µm in (A) and (C), 500 nm in (B), (D) and (K), 1 µm in (E), (F) and (J), and 20 µm in (I).
3.5 ± 0.41 ng d−1 of VEGF per mg from the smaller
PEA 4F4 MS (figure 1(H)).
This second phase has been associated with poly-
mer matrix surface erosion (Memanishvili et al 2016)
in the spheres, being responsible for sustained drug
diffusion to the medium during at least 90 d. Here
we found that after 90 d in vitro, 68% of VEGF
had been released from the PEA 4F4 MS. The
amount of VEGF remaining was 30 ± 0.4 ng per
mg MS. Partial degradation of the MS via matrix
surface erosion was shown by electron microscopy
(figures 1(I)–(K)).
3.2. Injection of VEGF-loaded and non-loaded PEA
4F4MS improves functional recovery without
affecting infarct volume after stroke
Mice were subjected to dMCAO and, 1 week later,
randomly distributed to three groups and injec-
ted with PBS, or non-loaded or VEGF-loaded MS,
respectively, into cerebral cortex close to the ischemic
injury. One sham-operated group was injected with
PBS into cerebral cortex and used as control for stroke
damage. Sensory and motor functions were evalu-
ated before and at 2, 4 and 8 weeks after stroke using
neurological score (mNSS) and adhesive removal
tests. At 2 and 6 d after stroke or sham proced-
ure, but before PBS or MS injection, all groups sub-
jected to dMCAO showed significant neurological
impairments compared to Sham + PBS group as
evidenced by higher neurological score (figure 2(A):
Interaction; F12,108 = 3.937, p < 0.0001). Animals
injected with VEGF-loaded MS demonstrated more
rapid improvement of neurological score, which
did not differ from that of Sham + PBS group
at 2 weeks after stroke and 1 week after injection
(figure 2(A)). In contrast, stroke-subjected anim-
als injected with PBS or non-loaded MS exhib-
ited no signs of recovery at this time point (fig-
ure 2(A)). When assessed at later time-points, 4 and
8 weeks after stroke, animal groups with VEGF-
loaded and non-loaded MS both exhibited neurolo-
gical score similar to the Sham+ PBS group, whereas
stroke-injured animals injected with PBS remained
impaired.
We also assessed performance of the mice in the
adhesive removal test. Animals subjected to dMCAO
and injected with PBS needed significantly longer
time to contact tape at 2 and 4 weeks and to
remove tape at 2 weeks after stroke as compared
to Sham + PBS group (figure 2(B): Interaction;
6
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Figure 2. Effect of injection of VEGF-loaded and non-loaded PEA 4F4 MS on functional recovery and infarct volume after stroke.
(A)–(B) Neurological score (A) and performance in adhesive removal test (B) at different time points after dMCAO or sham
procedure and subsequent injection with PBS, or non-loaded or VEGF-loaded MS into cerebral cortex (nsham = 6; nPBS = 7;
nMS = 9; nVEGF-MS = 9). ∗P < 0.05 compared to Sham+ PBS group (A) or all other groups (B), two-way ANOVA. (C)
Distribution of ischemic injury (depicted by asterisk) in mice subjected to dMCAO and injected with PBS (left), non-loaded MS
(middle) or VEGF-loaded MS (right). (D) Mean volume of ischemic lesion at 8 weeks after dMCAO in animals injected with PBS,
non-loaded MS and VEGF-loaded MS (n= 4 for each group).
F9,81 = 3.544, p = 0.001; and F9,81 = 1.814, p = 0.07;
for time to contact and time to remove, respect-
ively). In contrast, animals injectedwith eitherVEGF-
loaded or non-loaded MS showed no impairment at
2 and 4 weeks. At 8 weeks after stroke, also anim-
als from the dMCAO + PBS group had recovered
in both parameters of the adhesive removal test
(figure 2(B)).
Taken together, these findings provide evidence,
first, that VEGF-loaded MS can give rise to accel-
erated functional recovery after stroke and, second,
that both implantation of loaded and non-loadedMS
can promote long-term improvement. We hypothes-
ized that the various behavioral outcomes could be
correlated to the volume of the ischemic lesion but,
arguing against this interpretation, found no differ-
ences between the groups (figures 2(C) and (D)).
3.3. Injection of PEA 4F4MS loaded with VEGF
increases tissue VEGF levels and promotes
angiogenesis after stroke
We analyzed the presence of MS and distribution
of VEGF at 8 weeks after stroke using anti-VEGF
immunostaining (figure 3). Based on their auto-
fluorescence, MS were detected in 78% and 56% of
the animals implanted with VEGF-loaded and non-
loaded MS, respectively. In those brains in which
MS were not found, we observed a cavity located at
the site of MS injection. It is conceivable that the
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Figure 3. Effect of injection of VEGF-loaded and non-loaded PEA 4F4 MS on VEGF immunoreactivity and angiogenesis after
stroke. (A) Fluorescence photomicrographs of the coronal section at a level of injection site for PBS in sham-treated mouse
cerebral cortex, showing staining with blood vessel-specific marker CD31 (red) and lack of VEGF (in green) immunoreactivity.
(B)–(C) Fluorescence photomicrographs showing coronal sections of mice subjected to MCAO and injected with non-loaded (B)
or VEGF-loaded (C) MS, stained for VEGF (green) and CD31 (red). (D) Fluorescence photomicrographs of the coronal section at
a level of the implantation site for VEGF-loaded MS in dMCAO-injured mouse cerebral cortex, showing absence of damage in
host neurons stained with MAP2 (red) around the VEGF (in green) immunoreactive MS. Insets in (A)–(D) show higher
magnification of the area depicted with small white squares. (E)–(F) Quantification of area immunoreactive for VEGF (E) and of
blood vessel density (F) in sham-operated mice (n= 6) and in mice subjected to dMCAO and injected with either PBS (n= 7) or
non-loaded (n= 7) or VEGF-loaded MS (n= 9). For each animal, n= 3 samples. ∗P < 0.05, one-way ANOVA. Scale bar on
A= 200 µm for the coronal sections and 30 µm for large insets.
MS had been washed out during fixation, section-
ing or the complex process of immunostaining on
free-floating sections. Figure 3 shows a representat-
ive image of a section in which VEGF-loaded MS
are clearly visible, being distributed within the par-
enchyma without forming clumps.
High VEGF immunoreactivity was detected close
to the loaded MS, suggesting successful release of
VEGF (figure 3). In agreement, quantification of
the VEGF immunoreactive area in the stroke-injured
hemisphere showed a significant increase of VEGF
levels only in animals injected with loaded MS (fig-
ures 3(C)–(E)).
We hypothesized that release of VEGF from the
loaded MS may increase angiogenesis, which could
contribute to the accelerated functional improvement
evidenced by the neurological score. Vessel density in
dMCAOanimals injectedwith PBSwas similar to that
of sham-operated mice and, thus, we detected no sig-
nificant influence on angiogenesis by the stroke injury
per se at 8 weeks. Providing evidence for the regula-
tion of angiogenesis by VEGF released from the injec-
ted, loaded MS in stroke-subjected mice, we found
markedly higher vessel density in these mice as com-
pared to animals injected with non-loadedMS or PBS
(figures 3(B) and (F)).
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Figure 4. Effect of injection of VEGF-loaded and non-loaded PEA 4F4 MS on inflammatory response in stroke-injured brain
injected with non-loaded or VEGF-loaded PEA 4F4 MS. (A)–(B) Fluorescence photomicrographs showing Iba1+microglia (in
red) and activated (ED1+) microglia (in green) in the area adjacent to the ischemic lesion of mice injected with PBS (A) or
VEGF-loaded MS (B). (C)–(D) Quantification of number of Iba1+ cells (C) and percentage of Iba1+ cells expressing ED1 (D) in
ipsilateral hemisphere of sham-operated mice and mice subjected to dMCAO and injected with PBS or non-loaded or
VEGF-loaded MS into cerebral cortex. (E) Quantification of number of Iba1+ cells with ramified, intermediate and activated
(amoeboid or rounded) morphology in ipsilateral hemisphere of the same animal groups (n= 3 samples for each group).
∗P < 0.05 compared with other groups, $P < 0.05 compared to sham+ PBS and dMCAO+ PBS groups, one-way ANOVA. Scale
bar= 100 µm.
3.4. Injection of both non-loaded and
VEGF-loaded PEA 4F4MS reduces inflammatory
response after stroke
Inflammation is an important player in stroke-
induced neuronal loss but also contributes to tissue
repair (Benakis et al 2014, Elali and Jean LeBlanc
2016, Wattananit et al 2016). To determine the effect
of injected MS on the inflammatory response after
stroke, the degree of microglia activation was ana-
lyzed at 8 weeks after the insult (figures 4(A) and
(B)). In animals subjected to dMCAO and injected
with PBS, we found a significant increase both in the
total number of Iba1+ cells, mainly staining resid-
ent microglia (figure 4(C)), and the percentage of
activated Iba1+/ED1+microglia (figure 4(D)) in the
injured hemisphere as compared to sham-operated
animals. We also assessed the degree of microglia
activation based on their morphology. Ramified
microglia are considered to be in resting state while
intermediate, amoeboid and round microglia repres-
ent progressively more activated populations (Lehr-
mann et al 1997, Thored et al 2009). We found that
the numbers of intermediate, amoeboid and round
microglia were increased in dMCAO-subjected anim-
als injected with PBS (figure 4(E)). Interestingly,
injection of both non-loaded and VEGF-loaded MS
mitigated the increase of both the total number of
microglia and their degree of activation after stroke
(figures 4(A)–(E)), with no differences between the
groups.
3.5. Injection of PEA 4F4MS loaded with VEGF
induces increased number of NG2 cells expressing
VEGF after stroke
In sham-operated and PBS-injected animals, we
found VEGF immunoreactive cells in the ventricular
wall including subventricular zone, and less intensely
stained cells in corpus callosum. In all animal groups
subjected to dMCAO, the number of VEGF+ cells in
the corpus callosum and the intensity of immunos-
taining of individual cells was substantially increased
(supplemental figure S1).
Since VEGF immunoreactivity was increased in
the areas surrounding the VEGF-loaded MS (figure
3), we determined the identity of VEGF+ cells close
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to the MS injection using co-labeling with cell type-
specific antibodies. Only few GFAP+ astrocytes co-
expressed VEGF in the periphery of the MS injec-
tion site (figures 5(A) and (B)). No co-localization of
VEGF and the microglia- and pericyte-specific mark-
ers, Iba1 and CD13, respectively, was found (data not
shown). In contrast, we found co-expression of VEGF
in NG2+ cells in the corpus callosum and in the peri-
lesion area (figure 5(C)). These cells represent a type
of neuroglia distinct from mature astrocytes and oli-
godendrocytes as well as from microglia.
Quantification of NG2+/VEGF+ cells showed
higher numbers in animals injected with MS (non-
loaded or loaded with VEGF) as compared to sham-
operated and stroke-subjected animals injected with
PBS in both hemispheres (figure 5(D)), predomin-
antly in the injured hemisphere. Animals injected
with VEGF-loaded MS showed higher numbers of
NG2+/VEGF+ cells as compared to those injected
with non-loaded MS (figure 5(D)) in both hemi-
spheres. In parallel, we observed increased number of
NG2+ cells in the same groups (figure 5(E)). To what
extent VEGF production was increased by the NG2+
cells themselves or VEGF originated from theMS and
was taken up by the NG2+ cells could not be estab-
lished.
4. Discussion
Here we describe, for the first time, the develop-
ment of PEAMS for intracerebral injection and long-
term delivery of a growth factor into the injured
adult brain. The PEA MS seem particularly attractive
for this purpose by combining the excellent thermal
and mechanical properties of polyamides with the
biocompatibility and biodegradability of polyesters
(Rodriguez-Galan et al 2011, Winnacker and Rieger
2016). In addition, the PEA MS are known to show
prolonged and controlled release profile of a variety of
drugs and proteins, lack of side effects of degradation
products, and versatility during fabrication (Win-
nacker and Rieger 2016). Moreover, these polymers
release the drug by a combination of diffusion and
polymer degradation, and because of the biodegrad-
ability do not require surgical removal when drug
application is finished (Fonseca et al 2014).
Double emulsion solvent evaporation is one of the
most commonly used techniques for encapsulation
of hydrophilic molecules. One limitation is the mod-
erate encapsulation efficiency (for review see (Iqbal
et al 2015)). The encapsulation efficiency observed
here (62.7%) is comparable to that reported in pre-
vious studies, ranging between 51% and 60% (Yang
et al Karal-Yilmaz et al 2000, Emami et al 2009, 2011,
Herran et al 2013a). In these studies, the w/o/w tech-
nique was used to prepare protein-loaded polymeric
microparticles, and the observed moderate encapsu-
lation efficiency was attributed to drug leakage to the
aqueous external phase.
Another important parameter in determining the
kinetics of protein release from MS is the volumet-
ric loading. Relatively high volumetric loadings are
required to ensure that a large portion of the drug is
released from polymers (Amsden and Cheng 1995).
However, high protein loading may provoke an ini-
tial burst of fast release, as some protein becomes
trapped on the surface of the polymer matrix during
the manufacturing process (Huang and Brazel 2001).
Low loading should also be avoided as a substantial
fraction of the proteinmay be trapped inside themat-
rix, never to be released (Siegel et al 1989). There-
fore, drug loadings should be kept sufficiently small to
ensure that the release is governed by polymer erosion
and not protein diffusion (Siegel et al 1989). Our
results demonstrate that the volumetric loading of
VEGF in theMS achieved here gave rise to a sustained
release of the protein over time and that only a small
fraction of the loaded protein was released through
diffusion.
Despite the moderate encapsulation efficiency
and volumetric loading in our study, the gener-
ated VEGF-loaded PEA 4F4 MS were releasing VEGF
in vitro for a long time, at least up to 90 d. This
release, facilitated by the enzymatic degradation of
PEA, occurs via surface erosion (Kropp et al 2014).
The impregnated lipase cleaves ester bonds, trigger-
ing the degradation (Tsitlanadze et al 2004, Murase
et al 2015).
It should be underlined that no accumulation
of acidic byproducts is observed during the surface
erosion degradation of PEAs (Mihov et al 2010, Ghaf-
far et al 2011, Fonseca et al 2014). As 4F4 PEA
degrades, it produces small quantities of weak acidic
products (Katsarava et al 2016). Thus, no drastic
decrease of pH occurs that would provoke a signific-
ant loss of protein bioactivity. In accordance, evid-
ence for retention of protein bioactivity using PEAs
as carriers has been reported previously. VEGF phos-
phorylates VEGFR2 in human endothelial cells after
release fromPEAMS (Caolo et al 2016). Proteins such
as WNT3A and BMP4, as well as fibroblast growth
factor 9 (FGF9) and Chemokine (C–X–C motif) lig-
and 1 (CXCL1) retain their biological activity in PEA-
based carriers (Said et al 2014, Caolo et al 2016,
Memanishvili et al 2016). In contrast, degradation of
PLGA occurs through bulk erosion and its hydrolysis
leads to the accumulation of acidic monomers, lactic
and glycolic acids with pKa 3.86 and 3.83, respect-
ively, causing significant reduction of pH and denat-
uration of encapsulated proteins (Bittner et al 1998,
Lai and Topp 1999, van de Weert et al 2000, Ye et
al 2010). Protein instability during release has also
been attributed to a local pH drop and the acidic
microenvironment inside the microparticles (Park
et al 1995, van de Weert et al 2000, Determan et al
2006, Mundargi et al 2008).
Both the non-loaded and VEGF-loaded PEA 4F4
MS enhanced behavioral recovery after injection into
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Figure 5. Effect of injection of non-loaded or VEGF-loaded PEA 4F4 MS on number of NG2+ cells expressing VEGF in
stroke-injured brain. (A) Fluorescence photomicrographs showing absence of colocalization of VEGF (green) and astrocytic
marker GFAP (red) in the area adjacent to the ischemic damage of a mouse injected with VEGF-loaded MS. (B) Higher
magnification of the area depicted with white square in (A). (C) Fluorescence photomicrographs showing colocalization of VEGF
(green) and NG2 (red) in the area adjacent to the ischemic lesion of a mouse injected with VEGF-loaded MS. (D)–(E)
Quantification of number of NG2+/VEGF+ (D) and NG2+ cells (E) in ipsilateral and contralateral hemisphere of
sham-operated, PBS-injected mice and mice subjected to dMCAO and injected with PBS, or non-loaded or VEGF-loaded MS
into cerebral cortex. ∗P < 0.05 compared to other groups, $P < 0.05 compared to sham+ PBS and dMCAO+ PBS groups,
respectively, one-way ANOVA. Scale bars= 100 µm in (A) and (C), and 20 µm in (B).
the stroke-injured mouse cerebral cortex. Several
lines of evidence support the conclusion that bio-
logically active VEGF was efficiently released long-
term from the loaded MS also into the brain tissue
environment: First, at 7 weeks after injection (8 weeks
after stroke), we observed VEGF+ PEA 4F4 MS in
the parenchyma and high VEGF immunoreactivity
close to the loaded PEA 4F4 MS. Accordingly, signi-
ficant increase of VEGF tissue levels was found only
in animals with loaded PEA 4F4 MS. Second, the
PEA 4F4 MS loaded with VEGF induced a markedly
higher vessel density in the injured hemisphere as
compared to non-loaded PEA 4F4 MS, in agreement
with the notion that VEGF is a pro-angiogenic factor
(Shibuya 2009). Third, we observed a higher num-
ber of NG2+ neuroglia cells in both hemispheres in
animals with VEGF-loaded PEA 4F4MS as compared
to non-loadedMS. Interestingly, NG2+ glia cells have
been implicated in vessel network formation dur-
ing embryonic development (Minocha et al 2015).
Finally, injection of VEGF-loaded PEA 4F4 MS gave
rise to more rapid recovery (already at 2 weeks after
the insult) of neurological score as compared to non-
loaded PEA 4F4MS. This specific action of VEGF is in
line with previous findings demonstrating behavioral
improvements following different modes of delivery
of this growth factor after stroke (Greenberg and Jin
2013).
11
Biomed. Mater. 15 (2020) 065020 T Memanishvili et al
Interestingly, intracerebral injection of not only
the VEGF-loaded but also the non-loaded PEA 4F4
MS gave rise to post-stroke improvement in neuro-
logical score and adhesive removal test. It is incon-
ceivable that these effects of the MS were due to
mechanical injury to the cortical tissue, associated
with inflammation, caused by the 1 µl injection of
the PEA 4F4 MS solution in both animal groups.
Thus, intracerebral injection of PEA MS into intact
brain (Memanishvili et al 2016), subconjunctival and
intravitreal injection of PEA fibrils (Kropp et al 2014),
intramuscular application for intradiscal delivery of
PEA MS (Willems et al 2017) and intra-articular
injections of PEA MS (Janssen et al 2016) evoked
no significant inflammatory response. In our study,
injection of stroke-damaged mice with PEA MS did
not influence the size of the lesion at 8 weeks after
insult. This fact suggests that the beneficial effect is
not mediated through neuroprotection but by creat-
ing a microenvironment that improves tissue remod-
eling.
Our data provide evidence that PEA MS can
exhibit direct biological effects by themselves, includ-
ing improvement of post-stoke recovery, without
being loaded with any factors or molecules. In line
with this idea, both FGF9-loaded and non-loaded
PEA supported the proliferation of fibroblasts for
5 d even under serum-depleted conditions (Said et
al 2014). We hypothesized that the beneficial action
of both non-loaded MS and loaded MS observed
in our experiment could be related to an anti-
inflammatory effect. In support, monocytes have
been reported to secrete lower levels of the pro-
inflammatory cytokines, interleukin (IL)-6 and IL-
1β, into the culture supernatant when adherent to
PEA as compared to PLGA or poly(butyl methac-
rylate) (PBMA) (DeFife et al 2009). Also, monocytes
growing on PEA exhibited more than 3-fold higher
secretion of IL-1 receptor antagonist as compared to
monocytes on other polymers (DeFife et al 2009). IL-
1 receptor antagonist is a native inhibitor of IL-1β
that competitively binds receptors for IL-1 and blocks
pro-inflammatory signaling. We found that VEGF-
loaded and non-loaded PEA 4F4MS had similar anti-
inflammatory effect at 7 weeks after injection into the
stroke-injured brain, as evidenced by lower number
of activated microglia and macrophages with inter-
mediate and amoeboid/rounded morphology.
It has been shown that VEGF could be neuropro-
tective after stroke (Sun et al 2003). Our finding that
the intracerebral injection of VEGF-loaded and non-
loaded PEA 4F4MS in stroke-damaged mice induced
behavioral improvement but was not accompanied by
alterations in infarct size argues against a neuropro-
tective mechanism of action. In fact, enhanced post-
stroke functional recovery without changes in infarct
volume has been observed previously in several stud-
ies, e.g. following intracerebral transplantation of
human stem cell-derived neurons and blockade of
monocyte recruitment to the ischemic brain (Oki et al
2012, Tornero et al 2013, Jin et al 2014, Memanishvili
et al 2016).We hypothesize that the beneficial effect of
the intracerebral PEA MS injection is due to the cre-
ation of a microenvironment which improves tissue
remodeling and stimulates neural plasticity.
As we and others have shown, brain inflamma-
tion including activation of microglia and intracereb-
ral infiltration of macrophages plays an important
role during the recovery phase after stroke (Rajkovic
et al 2018). Taken together, our findings are consist-
ent with the hypothesis that the recovery-promoting
effect of PEA 4F4 MS could be attributed to an anti-
inflammatory action.
In conclusion, we demonstrate in the present
study the usefulness of PEA 4F4 MS for intracerebral
delivery of molecules to the injured brain. This sys-
tem for long-term administration of growth factors
regulating, e.g. neurogenesis, angiogenesis and neural
plasticity, as shown here, and of molecules which
can direct the differentiation of endogenous or trans-
planted stem cells to a specific cellular fate (Meman-
ishvili et al 2016) opens up new possibilities for brain
repair. The future therapeutic potential of PEA MS is
strengthened by their anti-inflammatory action and
biocompatibility. However, from a clinical perspect-
ive, intracerebral delivery of molecules with the aim
to promote functional restoration using PEA 4F4 MS
as vehicle is still in an early phase and the usefulness
of this strategy needs to be explored in much more
detail in experimental studies.
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